-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Enlivex Therapeutics, Raises Price Target to $13

Benzinga·01/12/2026 11:24:40
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and raises the price target from $7 to $13.